{
  "ticker": "CSL.AX",
  "company": "CSL Limited",
  "hypotheses": {
    "T1": {
      "label": "Growth/Recovery",
      "description": "Plasma collections normalise; Vifor acquisition delivers synergies; pipeline catalysts",
      "survival_score": 0.58,
      "status": "MODERATE",
      "weighted_inconsistency": 2.5,
      "last_updated": "2026-02-14T09:30:00+11:00"
    },
    "T2": {
      "label": "Managed/Base Case",
      "description": "Steady-state compounder: high single-digit earnings growth, premium valuation sustained",
      "survival_score": 0.75,
      "status": "HIGH",
      "weighted_inconsistency": 1.0,
      "last_updated": "2026-02-14T09:30:00+11:00"
    },
    "T3": {
      "label": "Risk/Downside",
      "description": "Vifor integration drags; plasma margin recovery slower than guided; FX headwinds",
      "survival_score": 0.33,
      "status": "LOW",
      "weighted_inconsistency": 4.2,
      "last_updated": "2026-02-14T09:30:00+11:00"
    },
    "T4": {
      "label": "Disruption",
      "description": "Gene therapy disrupts immunoglobulin demand; biosimilar erosion of key products",
      "survival_score": 0.12,
      "status": "VERY_LOW",
      "weighted_inconsistency": 7.1,
      "last_updated": "2026-02-14T09:30:00+11:00"
    }
  },
  "dominant": "T2",
  "confidence": "HIGH",
  "alert_state": "NORMAL",
  "alert_started": null,
  "current_price": 285.50,
  "last_flip": {
    "date": "2025-08-20",
    "from": "T1",
    "to": "T2",
    "trigger": "FY25 result in-line but guidance conservative; plasma margin recovery on track but gradual",
    "price_at_flip": 278.00,
    "from_survival": 0.36,
    "to_survival": 0.72
  },
  "narrative_history": [
    {
      "date": "2025-02-15",
      "from": "T2",
      "to": "T1",
      "trigger": "H1 FY25 earnings beat; Vifor synergies ahead of schedule; upgraded FY25 guidance",
      "price_at_flip": 305.00,
      "from_survival": 0.40,
      "to_survival": 0.78
    }
  ],
  "evidence_items": [
    {
      "id": "CSL_FY25_RESULT",
      "type": "EARNINGS_REPORT",
      "source": "ASX Filing",
      "epistemic_tag": "Under Oath (statutory)",
      "date": "2025-08-20T08:00:00+11:00",
      "summary": "FY25 NPATA $3.2B in-line; FY26 guidance 7-10% growth (conservative)",
      "diagnosticity": "HIGH",
      "hypothesis_impact": {
        "T1": "NEUTRAL",
        "T2": "CONSISTENT",
        "T3": "INCONSISTENT",
        "T4": "INCONSISTENT"
      },
      "decay": {
        "full_weight_days": 90,
        "half_life_days": 120
      },
      "active": true
    },
    {
      "id": "CSL_PLASMA_COLLECTIONS",
      "type": "OPERATIONAL_DATA",
      "source": "Investor Day",
      "epistemic_tag": "Motivated (corporate)",
      "date": "2025-11-10T10:00:00+11:00",
      "summary": "Plasma collections +15% YoY; cost per litre declining but above pre-COVID levels",
      "diagnosticity": "MEDIUM",
      "hypothesis_impact": {
        "T1": "CONSISTENT",
        "T2": "CONSISTENT",
        "T3": "INCONSISTENT",
        "T4": "NEUTRAL"
      },
      "decay": {
        "full_weight_days": 60,
        "half_life_days": 60
      },
      "active": true
    }
  ],
  "price_signals": [],
  "editorial_override": null,
  "price_history": [
    280.00, 281.50, 282.00, 283.00, 283.50,
    284.00, 283.80, 284.20, 284.50, 284.80,
    285.00, 285.20, 284.90, 285.10, 285.30,
    285.40, 285.50, 285.60, 285.40, 285.50,
    285.60, 285.50
  ],
  "weighting": null
}
